Skip to main content
SpringerLink
Log in

Interferon Trials in the Management of Malignant Melanoma and Other Neoplasms: An Overview

  • Chapter
Basic and Clinical Aspects of Malignant Melanoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 35))

Abstract

Interferons comprise a family of glycoproteins which are endogenously produced by cells in response to viral infections, double-stranded RNA, mitogens, or small molecular weight agents. Issacs and Lindeman initially coined the term ‘interferon’ to describe a macromolecular particle which had the properties of an interfering agent to viral infectivity in the chick chorio-allantoic membrane model [1]. Since their pioneering discovery, there has been keen interest in the biological characteristics of these unique substances.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Isaacs A, Lindenmann J: Virus interference: I. The interferon. Proc Roy Soc B 147:258–267, 1957.

    Article  CAS  Google Scholar 

  2. Taniguchi T, Mantei N, Schwarzstein M, et al: Human leukocyte and fibroblast interferons are structurally related. Nature 285:547–549, 1980.

    Article  PubMed  CAS  Google Scholar 

  3. Epstein DA, Torrence PF, Friedman RM: Double-stranded RNA inhibits a phosphoprotein phosphatase present in interferon-treated cells. Proc Natl Acad Sci USA 77:107–111, 1980.

    Article  PubMed  CAS  Google Scholar 

  4. Ball LA, White CN: Nuclease activation by double-stranded RNA and by 2′, 5′-oligoadenylate in extracts of interferon-treated chick cells. Virology 93:348–356, 1979.

    Article  PubMed  CAS  Google Scholar 

  5. Wheelock EF: Interferon-like virus inhibitor induced in human leukocytes by phytohemaglutinin. Science 149:310–311, 1965.

    Article  CAS  Google Scholar 

  6. Pfeffer LM, Murphy JS, Tamm I: Interferon effects on the growth and division of human fibroblasts. Exp Cell Res 121:111–120, 1979.

    Article  PubMed  CAS  Google Scholar 

  7. Creasey AA, Bartholomew JC, Merigan TC: Role of G0-G1-arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 77:1471–1475, 1980.

    Article  PubMed  CAS  Google Scholar 

  8. Gewert DR, Clemens M J: Inhibition by interferon of thymidine uptake and deoxyribonucleic acid synthesis in human lymphoblastoid cells. Biochem Soc Trans 8:353–354, 1980.

    PubMed  CAS  Google Scholar 

  9. Balkwill FR, Moodie EM, Freedman V, et al: Human interferon inhibits the growth of established human breast tumours in the nude mouse. Int J Cancer 30:231–235, 1982.

    Article  PubMed  CAS  Google Scholar 

  10. Kohno M, Ida N, Nago S, et al: Effects of human fibroblast interferon on human tumors transplated into nude mice: Sensitivity of human tumors to interferon. Gann 73:945–951, 1982.

    PubMed  CAS  Google Scholar 

  11. Berman B, Frankfort HM: The human interferon system. Int J Dermatol 21:12–18, 1982.

    Article  PubMed  CAS  Google Scholar 

  12. Sonnenfeld G, Mandel AD, Merigan TC: Time and dosage dependence of immuno-enhancement by murine type II interferon preparations. Cell Immunol 40:285–293, 1978.

    Article  PubMed  CAS  Google Scholar 

  13. Trinchieri G, Santoli D: Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1332, 1978.

    Article  PubMed  CAS  Google Scholar 

  14. Hamburg SI, Cassell GH, Rabinovitch M: Relationship between enhanced macrophage phagocytic activity and the induction of interferon by Newcastle disease virus in mice. J Immunol 124:1360–1364, 1980.

    PubMed  CAS  Google Scholar 

  15. Ida S, Hooks JJ, Siraganian RP, et al: Enhancement of IgE-mediated histamine release from human basophils by viruses: Role of interferon. J Exp Med 145:892, 1977.

    Article  PubMed  CAS  Google Scholar 

  16. Yaron M, Yaron I, Gurari-Rotman D, et al: Stimulation of prostaglandin E production in cultured human fibroblasts by poly I-C and human interferon. Nature 267:457, 1977.

    Article  PubMed  CAS  Google Scholar 

  17. Warren R, Kalamasz D, Storb R: Enhancement of human ADCC with interferon. Clin Exp Immunol 50:183–188, 1982.

    PubMed  CAS  Google Scholar 

  18. Einhorn S, Ahre A, Blomgren H, et al: Interferon and natural killer activity in multiple myeloma: Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-α. Int J Cancer 30:167–172, 1982.

    Article  PubMed  CAS  Google Scholar 

  19. Hannigan GE, Gewert DR, Williams BRG: Characterization and regulation of α-interferon receptor expression in interferon-sensitive and -resistant human lymphoblastoid cells. J Biol Chem 259:9456–9460, 1984.

    PubMed  CAS  Google Scholar 

  20. Zoon KC, Arnheiter H: Studies of the interferon receptors. Pharmac Ther 24:259–278, 1984.

    Article  CAS  Google Scholar 

  21. Salmon SE, Durie BGM, Young L, et al: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1(3):217–225, 1983.

    PubMed  CAS  Google Scholar 

  22. Von Hoff DD, Gutterman J, Portnoy B, et al: Activity of human leukocyte interferon in a human tumor cloning system. Cancer Chemother Pharmacol 8:99–103, 1982.

    Article  Google Scholar 

  23. Welander CE, Morgan TM, Homesley HD, et al: Combined recombinant human interferon alpha2 and cytotoxic agents studies in a clonogenic assay. Int J Cancer 35:721–729, 1985.

    Article  PubMed  CAS  Google Scholar 

  24. Twentyman PR, Workman P, Wright KA, et al: The effects of α and γ interferons on human ling cancer cells grown in vitro or as xenografts in nude mice. Br J Cancer 52:21–29, 1985.

    Article  PubMed  CAS  Google Scholar 

  25. Fisher PB, Kellogg C, Sheffield K, et al: Antitumor activity of interferon: In vitro studies on human melanoma. Proc Am Assoc Cencer Res 23:227 (Abstract 898), 1982.

    Google Scholar 

  26. Schiller JH, Willson JK, Bittner G, et al: Synergistic effects of human interferons (IFNS) on resistant melanoma cells in the human tumor colony forming assay (HTCFA). Proc Am Soc Clin Oncol 4:147, 1985.

    Google Scholar 

  27. Gutterman JU, Fine S, Quesada J, et al: Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 96(5):549–556, 1982.

    PubMed  CAS  Google Scholar 

  28. Sherwin SA, Knost JA, Fein S, et al: A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248(19):2461–2466, 1982.

    Article  PubMed  CAS  Google Scholar 

  29. Quesada JR, Rios A, Swanson D, et al: Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3(11): 1522–1528, 1985.

    PubMed  CAS  Google Scholar 

  30. Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399–406, 1980.

    PubMed  CAS  Google Scholar 

  31. Borden EC: Progress toward therapeutic application of interferons, 1979–1983. Cancer 54:2770–2776, 1984.

    Article  PubMed  CAS  Google Scholar 

  32. Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 2(4):336–352, 1984.

    PubMed  CAS  Google Scholar 

  33. Kirkwood JM, Ernstoff M: Melanoma: Therapeutic options with recombinant interferons. Semin Oncol 12(4):7–12, 1985.

    PubMed  CAS  Google Scholar 

  34. Krown SE, Burk MW, Kirkwood JM, et al: Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society Phase II trial. Cancer Treat Rep 68(5):723–726, 1984.

    PubMed  CAS  Google Scholar 

  35. Retsas R, Priestman TJ, Newton KA, et al: Evaluation of human lymphoblastoid interferon (HLBI) in metastatic malignant melanoma (MMM): A Phase II study (Abstract). Proc Am Soc Clin Oncol 22:371, 1981.

    Google Scholar 

  36. Retsas S, Priestman TJ, Newton KA, et al: Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer 51:273–276, 1983.

    Article  PubMed  CAS  Google Scholar 

  37. Creagan ET, Ahmann DL, Green SJ, et al: Phase II study of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma. Cancer 54:2844–2849, 1984.

    Article  PubMed  CAS  Google Scholar 

  38. Creagan ET, Ahmann DL, Green SJ, et al: Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 2(9): 1002–1005, 1984.

    PubMed  CAS  Google Scholar 

  39. Creagan ET, Ahmann DL, Green SJ, et al: Phase II study of recombinant leukocyte A interferon (IFN-rA) plus Cimetidine in disseminated malignant melanoma. J Clin Oncol 3(7):977–981, 1985.

    PubMed  CAS  Google Scholar 

  40. Creagan ET, Ahmann DL, Frytak S, et al: Phase II trials of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma: Result in 96 patients. Cancer Treat Rep 70(5): 619–624, 1986.

    PubMed  CAS  Google Scholar 

  41. Hawkins MJ, McCune CS, Speyer JL, et al: Recombinant alpha2 interferon (IFN-α 2) (SCH 30500) in patients with metastatic malignant melanoma (MMM): An ECOG pilot study. Proc Am Soc Clin Oncol 3:51, 1984.

    Google Scholar 

  42. Robinson WA, Kirkwood J, Harvey H, et al: Effective use of recombinant human α 2 interferon (IFN-α 2) in metastatic malignant melanoma (MMM): A comparison of two regimens. Proc Am Soc Clin Oncol 3:60, 1984.

    Google Scholar 

  43. Kirkwood JM, Harris JE, Vera R, et al: A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial. Cancer Res 45:863–871, 1985.

    PubMed  CAS  Google Scholar 

  44. Ikić D, Maricičc Z, Oresič V, et al: Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 1:1022–1024, 1981.

    Article  PubMed  Google Scholar 

  45. Mattson K, Holsti LR, Niiranen A, et al: Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer. J Biol Response Mod 4:8–17, 1985.

    PubMed  CAS  Google Scholar 

  46. Jones DH, Bleehen NM, Slater A J, et al: Human lymphoblastoid interferon in the treatment of small cell lung cancer. Br J Cancer 47:361–366, 1983.

    Article  PubMed  CAS  Google Scholar 

  47. Figlin RA, Callaghan M, Sarna G: Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum. Cancer Treat Rep 67:493–494, 1983.

    PubMed  CAS  Google Scholar 

  48. Chaplinski T, Laszlo J, Moore J, et al: Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma. Cancer Treat Rep 67:1009–1012, 1983.

    PubMed  CAS  Google Scholar 

  49. Silgais RM, Ahlgren JD, Neefe JR, et al: A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 54:2257–2261, 1984.

    Article  Google Scholar 

  50. Oberg K, Funa K, Alm G: Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 309:129–132, 1983.

    Article  PubMed  CAS  Google Scholar 

  51. Forbes A, Johnson PJ, Williams R: Recombinant human gamma-interferon in primary hepatocellular carcinoma. J R Soc Med 78:826–829, 1985.

    PubMed  CAS  Google Scholar 

  52. Berek JS, Hacker NF, Lichtenstein A, et al: Intraperitoneal recombinant alpha-interferon for ‘salvage’ immunotherapy in Stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. Cancer Res 45(9):4449–4453, 1985.

    Google Scholar 

  53. Niloff JM, Knapp RC, Jones G, et al: Recombinant leukocyte alpha interferon in advanced ovarian carcinoma. Cancer Treat Rep 69:895–896, 1985.

    PubMed  CAS  Google Scholar 

  54. Abdulhay G, DiSaia PJ, Blessing JA, et al: Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: A Gynecologic Oncology Group Study. Am J Obstet Gynecol 152:418–423, 1985.

    PubMed  CAS  Google Scholar 

  55. Ikić D, Kirhmajer V, Maricič Z, et al: Application of human leukocyte interferon in patients with carcinoma of the uterine cervix. Lancet 1:1027–1030, 1981.

    PubMed  Google Scholar 

  56. Ikić D, Brodarec I, Padovan I, et al: Application o human leukocyte interferon in patients with tumours of the head and neck. Lancet 1:1025–1027, 1981.

    Article  PubMed  Google Scholar 

  57. Connors JM, Andiman WA, Howarth CB, et al: Treatment of nasopharyngeal carcinoma with human leukocyte interferon. J Clin Oncol 3(6):813–817, 1985.

    PubMed  CAS  Google Scholar 

  58. Nagai M, Arai T: Clinical effect of interferon in malignant brain tumors. Neurosurg Rev 7:55–64, 1984.

    Article  PubMed  CAS  Google Scholar 

  59. Nakagawa Y, Hirakawa K, Ueda S, et al: Local administration of interferon for malignant brain tumors. Cancer Treat Rep 67:833–835, 1983.

    PubMed  CAS  Google Scholar 

  60. Caparros B, Rosen G, Cunningham-Rundles S: Phase II trial of interferon (IFN) in metastatic osteogenic sarcoma. Proc Am Assoc Cancer Res 23:121 (Abstract 474), 1982.

    Google Scholar 

  61. Padmanabhan N, Balkwill FR, Bodmer JG, Rubens RD: Recombinant DNA human interferon alpha-2 in advanced breast cancer: A Phase 2 trial. Br J Cancer l(l):55–60, 1985.

    Article  Google Scholar 

  62. Rohatiner AZS, Balkwill FR, Malpas JS, et al: Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML). Cancer Chemother Pharmacol 11:56–58, 1983.

    Article  PubMed  CAS  Google Scholar 

  63. Talpaz M, McCredie KB, Mavligit GM, et al: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62(3):689–692, 1983.

    PubMed  CAS  Google Scholar 

  64. Foon KA, Bottino GC, Abrams PG, et al: Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 78:216–220, 1985.

    Article  PubMed  CAS  Google Scholar 

  65. Quesada JR, Reuben J, Manning JT, et al: Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15–18, 1984.

    Article  PubMed  CAS  Google Scholar 

  66. Mellstedt H, Björkholm M, Johansson B, et al: Interferon therapy in myelomatosis. Lancet 1:245–247, 1979.

    Article  PubMed  CAS  Google Scholar 

  67. Foon KA, Sherwin SA, Abrams PG, et al: Treatment of advanced nonHodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148–1152, 1984.

    Article  PubMed  CAS  Google Scholar 

  68. Horning SJ, Merigan TC, Krown SE, et al: Human interferon alpha in malignant lymphoma and Hodgkin’s disease: Results of the American Cancer Society trial. Cancer 56(6): 1305–1310, 1985.

    Article  PubMed  CAS  Google Scholar 

  69. Bunn PA Jr, Foon KA, Ihde DC, Longo DL, Eddy S, Winkler CF, Veach SR, Zeffern J, Sherwin S, Oldham R: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med l(4):484–487, 1984.

    Google Scholar 

  70. Borgström S, von Eyben F, Flodgren P, et al: Regression of metastatic malignant melanoma induced by combination treatment with α-interferon and Cimetidine. Proceedings of the 13th International Cancer Conference, Seattle, 1982.

    Google Scholar 

  71. Borgström S, von Eyben FE, Flodgren P, et al: Human leukocyte interferon and Cimetidine for metastatic melanoma. N Engl J Med 307:1080–1081, 1982.

    PubMed  Google Scholar 

  72. Hill NO, Pardue A, Khan A, et al: Interferon and Cimetidine for malignant melanoma. N Engl J Med 308:386, 1983.

    Google Scholar 

  73. Flodgren P, Borgström S, Jönsson PE, et al: Metastatic malignant melanoma: Regression induced by combined treatment with interferon [HuIFN-α (Le)] and Cimetidine. Int J Cancer 32:657–665, 1983.

    Article  PubMed  CAS  Google Scholar 

  74. Slater LM, Wetzel MN, Cesario T: Combined interferon — antimetabolite therapy of murine L1210 leukemia. Cancer 48:5–9, 1981.

    Article  PubMed  CAS  Google Scholar 

  75. Gresser J, Maury C, Tovey M: Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice. Int J Cancer 17:647–651, 1976.

    Article  PubMed  CAS  Google Scholar 

  76. Chirigos MA, Pearson JW: Cure of murine leukemia with drug and interferon treatment. J Natl Cancer Inst 51:1367–1368, 1973.

    PubMed  CAS  Google Scholar 

  77. Kovach JS, Svingen PA: Enhancement of the antiproliferative activity of human interferon by polyamine depletion. Cancer Treat Rep 69:97–103, 1985.

    PubMed  CAS  Google Scholar 

  78. Kovach JS, Svingen PA: Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrahydro-2H-1, 3, 2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro. Invest New Drugs 2:155–159, 1984.

    Article  PubMed  CAS  Google Scholar 

  79. Creagan ET, Kovach JS, Long H J, et al: Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. J Clin Oncol 4:408–413, 1986.

    PubMed  CAS  Google Scholar 

  80. Marquet RL, Schellekens H, Westbroek DL, et al: Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats. Int J Cancer 31:223–26, 1983.

    Article  PubMed  CAS  Google Scholar 

  81. Lee SH, Chiu H, Renton KW, et al: Modulation by a human interferon of antitumor effects of cyclophosphamide against a lymphosarcoma in hamsters. Biochem Pharmacol 33:3439–3443, 1984.

    Article  PubMed  CAS  Google Scholar 

  82. Balkwill FR, Mowshowitz S, Seilman SS, et al: Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. Cancer Res 44:5249–5255, 1984.

    PubMed  CAS  Google Scholar 

  83. Balkwill FR, Moodie EM: Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 44:904–908, 1984.

    PubMed  CAS  Google Scholar 

  84. Adriamycin (Doxorubicin Hydrochloride), Package Insert, Adria Laboratories Inc, Columbus, Ohio, June 1983.

    Google Scholar 

  85. Carmichael J, Wolf CR, Balkwill FR, et al: Interferon potentiates the activity of cytotoxic drugs in non-small cell lung cancer. Proc Am Soc Clin Oncol 4:218, 1985.

    Google Scholar 

  86. Sato M, Yoshida H, Urata M, et al: Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture. Int J Oral Surg 13:35–44, 1984.

    Article  PubMed  CAS  Google Scholar 

  87. Carswell EA, Old LJ, Kassel RI, et al: An endotoxin induced serum factor which causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666–3670, 1975.

    Article  PubMed  CAS  Google Scholar 

  88. Soehnlen B, Liu R, Salmon SE: Recombinant tumor necrosis factors exhibit antitumor activity against clonogenic human tumor cells and synergism with gamma interferon. Proc Am Assoc Cancer Res 26:303, 1985.

    Google Scholar 

  89. Ruff MR, Gifford GE: Rabbit tumor necrosis factor: Mechanism of action. Infect Immun 31(1): 380–385, 1981.

    PubMed  CAS  Google Scholar 

  90. Czarniecki CW, Fennie CW, Powers DB, et al: Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons. J Virol 49:490–496, 1984.

    PubMed  CAS  Google Scholar 

  91. Fleischmann, Jr, WR, Fleischmann CM, Gindhart TD: Effect of hyperthermia on the antiproliferative activities of murine α-, β-, and γ-interferon: Differential enhancement of murine γ-interferon, Cancer Res 46:8–13, 1986.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. T. Creagan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, New York, USA

    Larry Nathanson M.D. (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Oncology-Hematology Division, Winthrop University Hospital, Suite 300, 222 Station Place North, Mineola, New York, 11501, USA

    Larry Nathanson M.D. (Professor of Medicine, Director) (Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Creagan, E.T. (1987). Interferon Trials in the Management of Malignant Melanoma and Other Neoplasms: An Overview. In: Nathanson, L. (eds) Basic and Clinical Aspects of Malignant Melanoma. Cancer Treatment and Research, vol 35. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2043-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2043-2_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9215-9

  • Online ISBN: 978-1-4613-2043-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation